Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will Another Alzheimer's Disease Drug Bite the Dust After Lilly's Latest Results?

TheMotleyFool

0 0

Will Another Alzheimer's Disease Drug Bite the Dust After Lilly's Latest Results?

There's a pressing need for safe and effective treatments for Alzheimer's disease. However, there haven't been many successes after years of research and development. Eli Lilly (NYSE: LLY) recently became the latest to disappoint with mixed results from a phase 2 study of donanemab. In this Motley Fool Live video recorded on March 17, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not yet another Alzheimer's disease drug could bite the dust after Lilly's results.

Source Fool.com

Like: 0

LLY

Share